Natural cytotoxicity receptor NKp30 (NKp30)

NKp30 (Natural cytotoxicity receptor NKp30, CD337) is a type I transmembrane glycoprotein of the immunoglobulin superfamily, classified as an activating receptor on human natural killer (NK) cells. It binds to ligands such as B7-H6, expressed primarily on tumor cells, initiating NK cell activation, cytotoxicity, and cytokine production[3][5][1]. The interaction exhibits high shape complementarity, with the FG loop of B7-H6 fitting snugly in a groove of the NKp30 receptor and exclusion of bulk solvent at the binding interface, enabling efficient immune recognition[1][2][4]. NKp30 is encoded by the NCR3 gene, and its function may be regulated by alternative splice variants. It is considered a promising drug target for cancer immunotherapy, although no direct therapies exist yet[6]. Safety challenges revolve around managing excessive immune activation. NKp30 is an important biomarker and functional modulator in cancer, infection, and immune-related disease contexts.

Other names

CD337NCR3Natural cytotoxicity receptor 3NKp30 receptor

Agonists would bind to or mimic ligand interaction, stimulating NK cell cytotoxicity and cytokine release. Antagonists or blocking antibodies could potentially inhibit unwanted NK cell activation. The ligand-dependent activation mechanism is primarily through recognition/binding of stress-induced ligands (i.e., B7-H6) on target cells.